Channa Striatus Extract on Albumin and Hs-CRP ESRD

This study is a randomised, double blind, placebo-controlled study in patients with ESRD on HD or CAPD based RRTs at Moewardi General Hospital in Surakarta, Indonesia from January to March 2021. Subjects were randomized to either a Channa striata or a placebo group and were given a three times daily dosage of 500 mg of Channa striatus extract or 500 mg maltodextrin, respectively for 21 days. Serum albumin and hs-CRP were measured at the baseline, and at the end of the study

Inclusion Criteria:ESRD patientUndergoing HD or CAPDExclusion Criteria:History of malignancy, autoimmune disease, active infectionSupplementation of albumin, herbal, antioxidant, steroid, immunosuppresive, heparin